Prevention and treatment of amyloidogenic diseases

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 7977316
APP PUB NO 20080248023A1
SERIAL NO

11842046

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Disclosed are pharmaceutical compositions and methods for preventing or treating a number of amyloid diseases, including Alzheimer's disease, prion diseases, familial amyloid neuropathies and the like. The pharmaceutical compositions include immunologically reactive amounts of amyloid fibril components, particularly fibril-forming peptides or proteins. Also disclosed are therapeutic compositions and methods which use immune reagents that react with such fibril components.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
ONCLAVE THERAPEUTICS LIMITEDDUBLIN, IE2

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Schenk, Dale B Burlingame, US 127 4442

Cited Art Landscape

Patent Info (Count) # Cites Year
 
Other [Check patent profile for assignment information] (2)
2002/0009,445 Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease 102 2001
2002/0197,258 Compositions and methods for preventing protein aggregation in neurodegenerative diseases 90 2002
 
NOVARTIS CORPORATION (1)
* 5866124 Antiidiotypic antibodies for high molecular weight-melanoma associated antigen 11 1996
 
RAMOT AT TEL-AVIV UNIVERSITY LTD. (1)
5688651 Prevention of protein aggregation 106 1994
 
SYNTEX, INCORPORATED (1)
5208036 N-(.omega., (.omega.-1)-dialkyloxy)- and N-(.omega., (.omega.-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor 147 1990
 
GLAXOSMITHKLINE LLC (1)
5854204 A.beta. peptides that modulate .beta.-amyloid aggregation 115 1996
 
UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (1)
2003/0147,882 METHODS FOR AMYLOID REMOVAL USING ANTI-AMYLOID ANTIBODIES 56 1999
 
ELI LILLY AND COMPANY (7)
5441870 Methods for monitoring cellular processing of .beta.-amyloid precursor protein 150 1992
5612486 Transgenic animals harboring APP allele having swedish mutation 142 1993
6114133 Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-.beta. peptide (x-.gtoreq.41) 106 1994
5593846 Methods for the detection of soluble .beta.-amyloid peptide 220 1995
5605811 Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein 92 1995
5837672 Methods and compositions for the detection of soluble .beta.-amyloid peptide 110 1995
6284221 Method for identifying .beta.-amyloid peptide production inhibitors 84 1996
 
TAKEDA PHARMACEUTICAL COMPANY LIMITED (2)
5750349 Antibodies to .beta.-amyloids or their derivatives and use thereof 154 1994
5955317 Antibodies to .beta.-amyloids or their derivatives and use thereof 99 1997
 
THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. (2)
5585100 Dual carrier immunogenic construct 78 1995
5955079 Dual carrier immunogenic construct 67 1995
 
DMS PHARMACEUTICAL INC. (1)
5231170 Antibodies to dense microspheres 88 1990
 
AMYLIN PHARMACEUTICALS, INC. (1)
5266561 Treatment of type 2 diabetes mellitus 20 1991
 
RASO, VICTOR (1)
2002/0136,718 Immunological control of beta-amyloid levels in vivo 64 2001
 
BRONSON NUTRITIONALS, LLC (5)
5869093 Treatment of immune diseases by oral administration of autoantigens 66 1994
5645820 Treatment of autoimmune diseases by aerosol administration of autoantigens 63 1995
5571499 Treatment of autoimmune diseases by aerosol administration of autoantigens 81 1995
5571500 Treatment of autoimmune diseases through administration by inhalation of autoantigens 64 1995
5641474 Prevention of autoimmune diseases by aerosol administration of autoantigens 61 1995
 
SCIOS NOVA, Inc. (3)
5220013 DNA sequence useful for the detection of Alzheimer's disease 79 1989
5187153 Methods of treatment using Alzheimer's amyloid polypeptide derivatives 82 1990
5387742 Transgenic mice displaying the amyloid-forming pathology of alzheimer's disease 197 1991
 
SUN HEALTH CORPORATION, INC. (1)
5192753 Anti-rheumatoid arthritic drugs in the treatment of dementia 91 1991
 
PROTHENA BIOSCIENCES LIMITED (1)
6923964 Active immunization of AScr for prion disorders 36 2000
 
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (3)
4666829 Polypeptide marker for Alzheimer's disease and its use for diagnosis 285 1985
5270165 Method of diagnosis of amyloidoses 80 1991
5750361 Formation and use of prion protein (PRP) complexes 69 1995
 
AUTOIMMUNE, INC. (4)
5849298 Treatment of multiple sclerosis by oral administration of bovine myelin 52 1993
5869054 Treatment of multiple sclerosis by oral administration of autoantigens 57 1995
5733547 Treatment of autoimmune arthritis by oral administration of type I or type III collagen 55 1995
5641473 Treatment of autoimmune diseases by aerosol administration of autoantigens 55 1995
 
Milkhaus Laboratory, Inc. (3)
5753624 Materials and methods for treatment of plaquing disease 91 1996
5851996 Materials and methods for treatment of plaquing diseases 95 1998
6294171 Methods for treating disease states comprising administration of low levels of antibodies 82 2001
 
Taurus International Manufacturing, Inc. (1)
5972269 Method of forming cavities in ceramic or metal injection molded parts using a fugitive core 16 1997
 
UNIVERSITY OF WASHINGTON (1)
5958883 Animal models of human amyloidoses 80 1995
 
UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (1)
6417178 Amyloid binding nitrogen-linked compounds for the antemortem diagnosis of alzheimer's disease, in vivo imaging and prevention of amyloid deposits 81 1997
 
TEKTRONIX, INC. (1)
5854996 Logic signal extraction 28 1994
 
Andrulis Pharmaceuticals Corp. (1)
5434170 Method for treating neurocognitive disorders 98 1993
 
ABBVIE BIOTHERAPEUTICS INC. (1)
5622701 Cross-reacting monoclonal antibodies specific for E- and P-selectin 65 1994
 
ALZA CORPORATION (1)
5972369 Diffusional implantable delivery system 83 1998
 
BAYER PHARMACEUTICALS CORPORATION (1)
5786180 Monoclonal antibody 369.2B specific for .beta. A4 peptide 83 1995
 
Antigenics, Inc. (2)
5057540 Saponin adjuvant 234 1990
5583112 Saponin-antigen conjugates and the use thereof 94 1992
 
ZOETIS SERVICES LLC (1)
5989566 Stable vaccine compositions for parenteral administration, a method for their use, and a process for their preparation 55 1996
 
EPIMMUNE INC. (1)
5736142 Alteration of immune response using pan DR-binding peptides 84 1994
 
The Scripps Research Institute (1)
5846533 Antibodies specific for native PrP.sup.Sc 79 1996
 
MASSACHUSETTS INSTITUTE OF TECHNOLOGY (1)
4883666 Controlled drug delivery system for treatment of neural disorders 243 1987
 
HUNTINGTON POTTER (1)
5780587 Compounds and methods for inhibiting .beta.-protein filament formation and neurotoxicity 81 1995
 
BHI Limited Partnership (1)
5643562 Method for treating amyloidosis 40 1995
 
UNIVERSITY OF ROCHESTER (1)
5231000 Antibodies to A4 amyloid peptide 138 1991
 
MCW RESEARCH FOUNDATION, INC. (1)
6057367 Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses 89 1997
 
ALTEON, INC. (1)
5935927 Compositions and methods for stimulating amyloid removal in amyloidogenic diseases using advanced glycosylation endproducts 79 1996
 
PROTEIN DESIGN LABS, INC. (1)
5530101 Humanized immunoglobulins 1216 1990
 
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (1)
6150091 Direct molecular diagnosis of Friedreich ataxia 54 1996
 
SONORAN DESERT CHEMICALS CORP. LLC (1)
* 5290762 Treatment of inflammation 22 1993
 
PARDRIDGE, WILLIAM (1)
5004697 Cationized antibodies for delivery through the blood-brain barrier 106 1987
 
NEW YORK UNIVERSITY (1)
5948763 Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits 21 1996
 
CYTRX CORPORATION (1)
5824322 Compositions and methods for growth promotion 58 1996
 
REGENTS OF THE UNIVERSITY OF MINNESOTA (3)
5837473 Methods of screening for agents affecting the deposition of .beta.-amyloid peptides on amyloid plaques in human tissue 54 1995
5877399 Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease 122 1996
6262335 Transgenic mice expressing APP mutant at amino acids 717, 721 and 722 59 1998
 
CEDARS-SINAI MEDICAL CENTER (1)
5679348 Immunotherapy for recurrent HSV infections 53 1992
 
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (1)
5744368 Methods for the detection of soluble amyloid .beta.-protein (.beta.AP) or soluble transthyretin (TTR) 66 1993
 
TRUSTEES OF BOSTON UNIVERSITY (1)
5262303 Ligand/anti-ligand assays for adherent proteins 7 1990
 
NATIONAL RESEARCH COUNCIL OF CANADA (1)
* 5773007 Vaccine compositions 35 1994
 
GLAXOSMITHKLINE BIOLOGICALS SA (1)
5776468 Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A 89 1996
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
BioArctic Neuroscience AB (4)
8859501 Protofibril-binding antibodies and their use in thereapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies 2 2013
9315569 Antibodies and vaccines for use in therapeutic and diagnostic methods for α-synuclein-related disorders 0 2014
8968734 Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for Parkinson's disease, dementia with lewy bodies and other α-synucleinopathies 0 2014
9084832 Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other α-synucleinopathies 0 2015
* Cited By Examiner

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jan 12, 2019
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jan 12, 2023
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00